Friday, 16 October 2026European Markets

CAIRN HOMES PLC And ABEO Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - cairn homes plc (c5h.ir) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
cairn homes plc (c5h.ir) €1.01 5.9% 10.59%
abeo (abeo.pa) €16.40 2.07% 8.59%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. cairn homes plc (c5h.ir)

5.9% forward dividend yield and 10.59% return on equity

cairn homes plc operates as a homebuilder in ireland. it is involved in the development and sale of residential properties, as well as rental of properties. the company was incorporated in 2014 and is based in dublin, ireland.

earnings per share

as for profitability, cairn homes plc has a trailing twelve months eps of €0.11.

pe ratio

cairn homes plc has a trailing twelve months price to earnings ratio of 9.22. meaning, the purchaser of the share is investing €9.22 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.59%.

volume

today's last reported volume for cairn homes plc is 337351 which is 60.53% below its average volume of 854855.

volatility

cairn homes plc's last week, last month's, and last quarter's current intraday variation average was a positive 0.81%, a negative 0.08%, and a positive 1.25%.

cairn homes plc's highest amplitude of average volatility was 1.21% (last week), 1.34% (last month), and 1.25% (last quarter).

yearly top and bottom value

cairn homes plc's stock is valued at €1.01 at 12:30 est, way below its 52-week high of €1.29 and way higher than its 52-week low of €0.80.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on apr 20, 2023, the estimated forward annual dividend rate is 0.06 and the estimated forward annual dividend yield is 5.9%.

more news about cairn homes plc.

2. abeo (abeo.pa)

2.07% forward dividend yield and 8.59% return on equity

abéo sa designs, manufactures, and distributes sports and leisure equipment in france and internationally. it offers gymnastics apparatus and landing mats, team sports equipment, physical education, climbing walls, and changing room fittings. it offers its products under the gymnova, janssen-fritsen, spieth gymnastics, schelde sports, spieth america, sportsafe, erhard sport, adec sport, o'jump, cannice, bosan, pcv, vogoscope, bigairbag, entre-prises, clip'n climb, top30, fun spot, climbat, france equipement, meta, prospec, navic, sanitec, suffixe, and sanelite brands. the company was founded in 1955 and is headquartered in rioz, france.

earnings per share

as for profitability, abeo has a trailing twelve months eps of €1.27.

pe ratio

abeo has a trailing twelve months price to earnings ratio of 12.91. meaning, the purchaser of the share is investing €12.91 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.59%.

more news about abeo.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com